NEXGEL, Inc. (NXGL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NEXGEL, Inc. (NXGL) Healthcare & Pipeline Overview

NEXGEL, Inc., founded in 1997, develops and manufactures high water content hydrogels, serving the wound care, diagnostics, drug delivery, and cosmetics markets. The company leverages electron beam cross-linking technology to create specialized aqueous polymer gels, positioning itself as a niche player in advanced medical materials.

What Is the Investment Thesis for NXGL?

NEXGEL, Inc. presents a focused investment opportunity within the specialized hydrogel market. With a market capitalization of $0.01 billion, the company's growth potential is tied to its ability to expand applications for its high water content hydrogels. A key value driver is the company's gross margin of 39.5%, indicating efficient production and pricing strategies. Upcoming catalysts include potential partnerships for expanded distribution and new product launches in the wound care and drug delivery segments. However, investors should be aware of the company's negative profit margin of -26.3%, which highlights the need for improved cost management and revenue scaling.

Based on FMP financials and quantitative analysis

NXGL Key Highlights

Market capitalization of $0.01 billion, reflecting its small-cap status and growth potential.

• Gross margin of 39.5%, indicating efficient production and pricing strategies in hydrogel manufacturing.
• Negative profit margin of -26.3%, highlighting the need for improved cost management and revenue scaling.
• Beta of 0.85, suggesting lower volatility compared to the broader market.
• Specialization in high water content hydrogels, targeting niche applications in wound care, diagnostics, drug delivery, and cosmetics.

Who Are NXGL's Competitors?

NXGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NXGL's Key Strengths?

Specialized expertise in hydrogel technology.

• Proprietary electron beam cross-linking process.
• Diverse applications across multiple sectors.
• Established presence in the wound care market.

What Are NXGL's Weaknesses?

Small market capitalization and limited financial resources.

• Negative profit margin indicating profitability challenges.
• Dependence on a limited number of key customers.
• Limited brand recognition compared to larger competitors.

What Could Drive NXGL Stock Higher?

Potential FDA clearance for new hydrogel-based wound care product in Q4 2026.

• Announcement of a strategic partnership with a major pharmaceutical company for transdermal drug delivery by Q3 2026.
• Expansion of sales and distribution network in Asia-Pacific region.
• Development of new hydrogel formulations for cosmetic applications.

What Are the Key Risks for NXGL?

Listing risk — at $0.2901 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -1.67 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-70.2%) — the business is not currently generating profit on shareholder capital.
• Regulatory delays in obtaining FDA clearance for new products.
• Increased competition from larger medical device companies.
• Fluctuations in raw material costs impacting gross margins.
• Dependence on key customer relationships for revenue generation.

What Are the Growth Opportunities for NXGL?

• Expansion in Wound Care Market: NEXGEL can capitalize on the growing wound care market, projected to reach $22 billion by 2028, by developing advanced hydrogel dressings. These dressings can incorporate antimicrobial agents or growth factors to promote faster healing and reduce infection rates. The timeline for product development and market entry is estimated at 2-3 years, offering a significant revenue stream.
• Strategic Partnerships for Drug Delivery: Collaborating with pharmaceutical companies to develop transdermal drug delivery systems using NEXGEL's hydrogels presents a substantial growth opportunity. The transdermal drug delivery market is expected to reach $8 billion by 2027. By partnering with established pharmaceutical firms, NEXGEL can leverage their distribution networks and regulatory expertise, accelerating market penetration.
• Penetration of the Cosmetics Industry: NEXGEL can expand its presence in the cosmetics industry by formulating hydrogel-based skincare products. The global skincare market is projected to reach $180 billion by 2027. Developing innovative hydrogel masks, moisturizers, and serums can attract a growing consumer base seeking advanced skincare solutions, with a potential launch within 1-2 years.
• Development of Medical Diagnostic Applications: NEXGEL's hydrogels can be utilized in medical diagnostic devices, such as biosensors and microfluidic chips. The medical diagnostics market is expected to reach $110 billion by 2028. By partnering with diagnostic companies, NEXGEL can develop specialized hydrogels for rapid and accurate disease detection, with a potential market entry in 3-4 years.
• Geographic Expansion into Emerging Markets: Expanding sales and distribution into emerging markets, such as Asia-Pacific and Latin America, presents a significant growth opportunity. These regions are experiencing rapid growth in healthcare spending and demand for advanced medical materials. Establishing partnerships with local distributors can facilitate market entry and drive revenue growth within 2-3 years.

What Threats Does NXGL Face?

• Competition from larger medical device and materials companies.
• Regulatory hurdles and compliance requirements.
• Potential for technological obsolescence.
• Economic downturn impacting healthcare spending.

What Are NXGL's Competitive Advantages?

• Specialized electron beam cross-linking technology.
• Expertise in high water content hydrogel formulation.
• Established relationships with medical device and pharmaceutical companies.
• Proprietary hydrogel formulations for specific applications.

What Does NXGL Do?

NEXGEL, Inc., established in 1997 and formerly known as AquaMed Technologies, Inc., is a manufacturer of high water content hydrogels. The company's core expertise lies in creating electron beam cross-linked and aqueous polymer hydrogels, which find applications across diverse sectors, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics. These hydrogels are designed to offer superior moisture retention and biocompatibility, making them suitable for advanced medical and cosmetic applications. NEXGEL's product portfolio includes a range of gel formats tailored to specific uses, such as wound dressings, diagnostic test components, and drug delivery patches. The company operates from its headquarters in Langhorne, Pennsylvania, focusing on innovation and quality in hydrogel manufacturing. NEXGEL aims to expand its market presence by developing new hydrogel formulations and applications, addressing unmet needs in the healthcare and cosmetics industries. The company changed its name to NEXGEL, Inc. in November 2019, marking a strategic shift to emphasize its focus on hydrogel technology.

What Products and Services Does NXGL Offer?

• Manufactures high water content hydrogels.
• Utilizes electron beam cross-linking technology.
• Develops aqueous polymer gels.
• Supplies hydrogels for wound care applications.
• Provides hydrogels for medical diagnostics.
• Offers hydrogels for transdermal drug delivery.
• Creates hydrogels for cosmetic products.

How Does NXGL Make Money?

• Manufactures and sells hydrogels to medical device companies.
• Supplies hydrogels to pharmaceutical companies for drug delivery systems.
• Sells hydrogels to cosmetic companies for skincare products.
• Generates revenue through direct sales and distribution agreements.

What Industry Does NXGL Operate In?

NEXGEL, Inc. operates within the medical instruments and supplies industry, a segment characterized by continuous innovation and demand for advanced materials. The global hydrogel market is projected to grow, driven by increasing applications in wound care, drug delivery, and regenerative medicine. NEXGEL's focus on high water content hydrogels positions it to capitalize on this trend, particularly in specialized applications. The competitive landscape includes larger medical device companies and specialty materials manufacturers. NEXGEL differentiates itself through its electron beam cross-linking technology and focus on niche markets.

Who Are NXGL's Key Customers?

• Medical device manufacturers specializing in wound care.
• Pharmaceutical companies developing transdermal drug delivery systems.
• Cosmetic companies producing skincare products.
• Diagnostic companies utilizing hydrogels in biosensors.

NEXGEL, Inc. (NXGL) Valuation Context

Relative to its peer group, NXGL's quantitative score of 22/100 is below the peer average of 68/100.

NXGL Revenue & Earnings Trend

In Q2 FY2026, NXGL generated $3.7M in top-line revenue, marking a sequential increase of 39.1%. The company recorded a net loss of $3.6M, with diluted EPS of $-0.40. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, NXGL averaged $-0.18 in diluted EPS.

Company Profile

NEXGEL, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Langhorne, US. The company is led by CEO Adam R. Levy. NXGL has traded publicly since 2021.

Return on equity for NEXGEL, Inc. stands at -70.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -69.7%, the inverse of the P/E and a quick read on earnings relative to price.

NEXGEL, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.67 places it in the distress zone, a signal of elevated financial risk.

NEXGEL, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 132.9% below estimates on average.

Over the past six months, NEXGEL, Inc. insiders filed 16 SEC Form 4 transactions — 9 sales and 7 purchases. On net that is roughly 2.8M shares acquired (about $1.9M) — insiders putting money in tends to read as conviction.

NXGL Financials

NXGL Latest News

NXGL Analyst Consensus

NXGL MoonshotScore

NEXGEL, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources